A neurobiological hypothesis of treatment-resistant depression-mechanisms for selective serotonin reuptake inhibitor non-efficacy

Frontiers in Behavioral Neuroscience

Volumn 8, Issue MAY, 2014, Pages

  Coplan, Jeremy D ^a   Gopinath, Srinath ^a   Abdallah, Chadi G ^b,c   Berry, Benjamin R ^d  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c National Center for PTSD   (United States)

^d Downstate Health Sciences University   (United States)

Author keywords

Autoreceptors; Dorsal raphe; Glutamate; Hippocampus; Lamotrigine; Selective serotonin reuptake inhibitors; Treatment resistant depression

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; DULOXETINE; KETAMINE; LAMOTRIGINE; LITHIUM; LURASIDONE; PLACEBO; QUETIAPINE; SEROTONIN 1A RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; VILAZODONE;

5 HT1A RECEPTOR GENE; 5 HTTLPR GENE; ABNORMAL BEHAVIOR; ANTIDEPRESSANT ACTIVITY; BIPOLAR DEPRESSION; BRAIN FUNCTION; BRAIN REGION; CLINICAL TRIAL (TOPIC); CONCEPTUAL FRAMEWORK; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; DRUG TREATMENT FAILURE; DYSTHYMIA; GENE; GENETIC POLYMORPHISM; HUMAN; HYPOMANIA; JITTERINESS SYNDROME; MAJOR DEPRESSION; MANIA; NERVE CELL PLASTICITY; NEUROBIOLOGY; NONHUMAN; REVIEW; SEROTONIN METABOLISM; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE;

EID: 84901268724     PISSN: 16625153     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnbeh.2014.00189     Document Type: Review

References (157)

1. Aghajanian, G. K., and Wang, R. Y. (1977). Habenular and other midbrain raphe afferents demonstrated by a modified retrograde tracing technique. Brain Res. 122, 229-242. doi:10.1016/0006-8993(77)90291-8
2. Akiskal, H. S., Akiskal, K. K., Lancrenon, S., Hantouche, E. G., Fraud, J. P., Gury, C., et al. (2006). Validating the bipolar spectrum in the French National EPIDEP Study: overview of the phenomenology and relative prevalence of its clinical prototypes. J. Affect. Disord. 96, 197-205. doi:10.1016/j.jad.2006.05.015
3. Akiskal, H. S., and Pinto, O. (1999). The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr. Clin. North Am. 22, 517-534. doi:10.1016/S0193-953X(05) 70093-9
4. Altieri, S. C., Garcia-Garcia, A. L., Leonardo, E. D., and Andrews, A. M. (2012). Rethinking 5-HT1A receptors: emerging modes of inhibitory feedback of rele- vance to emotion-related behavior. ACS Chem. Neurosci. 4, 72-83. doi:10.1021/ cn3002174
5. Amat, J., Baratta, M. V., Paul, E., Bland, S. T., Watkins, L. R., and Maier, S. F. (2005). Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat. Neurosci. 8, 365-371. doi:10.1038/nn1399
6. Angst, J., Cui, L., Swendsen, J., Rothen, S., Cravchik, A., Kessler, R. C., et al. (2010). Major depressive disorder with subthreshold bipolarity in the national comor- bidity survey replication. Am. J. Psychiatry 167, 1194-1201. doi:10.1176/appi. ajp.2010.09071011
7. Ansorge, M. S., Zhou, M., Lira, A., Hen, R., and Gingrich, J. A. (2004). Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Sci- ence 306, 879-881. doi:10.1126/science.1101678
8. Artigas, F., Adell, A., and Celada, P. (2006). Pindolol augmentation of antidepressant response. Curr. Drug Targets 7, 139-147. doi:10.2174/138945006775515446
9. Artigas, F., Romero, L., de Montigny, C., and Blier, P. (1996). Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci. 19, 378-383. doi:10.1016/S0166-2236(96) 10037-0
10. Atmaca, M., Kuloglu, M., Tezcan, E., and Buyukbayram, A. (2003). Switching to tianeptine in patients with antidepressant-induced sexual dysfunction. Hum. Psychopharmacol. 18, 277-280. doi:10.1002/hup.479
11. Bach, H., Huang, Y.-Y., Underwood, M. D., Dwork, A. J., Mann, J. J., and Arango, V. (2014). Elevated serotonin and 5-HIAA in the brainstem and lower sero- tonin turnover in the prefrontal cortex of suicides. Synapse 68, 127-130. doi:10.1002/syn.21695
12. Barbee, J. G., and Jamhour, N. J. (2002). Lamotrigine as an augmentation agent in treatment-resistant depression. J. Clin. Psychiatry 63, 737-741. doi:10.4088/JCP. v63n0813
13. Barbee, J. G., Thompson, T. R., Jamhour, N. J., Stewart, J. W., Conrad, E. J., Reimherr, F. W., et al. (2011). A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J. Clin. Psychiatry 72, 1405-1412. doi:10.4088/JCP.09m05355gre
14. Baumer, F. M., Howe, M., Gallelli, K., Simeonova, D. I., Hallmayer, J., and Chang, K. D. (2006). A pilot study of antidepressant-induced mania in pediatric bipolar disorder: characteristics, risk factors, and the serotonin transporter gene. Biol. Psychiatry 60, 1005-1012. doi:10.1016/j.biopsych.2006.06.010
15. Beasley, C. M. Jr., Sayler, M. E., Bosomworth, J. C., and Wernicke, J. F. (1991). High- dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression. J. Clin. Psychopharmacol. 11, 166-174. doi:10.1097/00004714- 199106000-00004
16. Beasley, C. M. Jr., Sayler, M. E., Weiss, A. M., and Potvin, J. H. (1992). Fluoxetine: activating and sedating effects at multiple fixed doses. J. Clin. Psychopharmacol. 12, 328-333. doi:10.1097/00004714-199210000-00006
17. Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., et al. (2000). Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351-354. doi:10.1016/S0006-3223(99)00230-9
18. Berman, R. M., Fava, M., Thase, M. E., Trivedi, M. H., Swanink, R., McQuade, R. D., et al. (2009). Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 14, 197-206.
19. Blier, P., and De Montigny, C. (1983). Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat. J. Neurosci. 3, 1270-1278.
20. Blier, P., and de Montigny, C. (1987). Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1, 470-480. doi:10.1002/syn.890010511
21. Blier, P., de Montigny, C., and Chaput, Y. (1987). Modifications of the sero- tonin system by antidepressant treatments: implications for the therapeutic response in major depression. J. Clin. Psychopharmacol. 7(6 Suppl.), 24S-35S. doi:10.1097/00004714-198712001-00003
22. Blier, P., Pineyro, G., El Mansari, M., Bergeron, R., and de Montigny, C. (1998). Role of somatodendritic 5-HT autoreceptorsinmodulating 5-HTneurotransmission. Ann. N. Y. Acad. Sci. 861, 204-216. doi:10.1111/j.1749-6632.1998.tb10192.x
23. Bonierbale, M., Lancon, C., and Tignol, J. (2003). The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr. Med. Res. Opin. 19, 114-124. doi:10.1185/030079902125001461
24. Bortolozzi, A., Castane, A., Semakova, J., Santana, N., Alvarado, G., Cortes, R., et al. (2012). Selective siRNA-mediated suppression of 5-HT1A autorecep- tors evokes strong anti-depressant-like effects. Mol. Psychiatry 17, 612-623. doi:10.1038/mp.2011.92
25. Bose, S. K., Mehta, M. A., Selvaraj, S., Howes, O. D., Hinz, R., Rabiner, E. A., et al. (2011). Presynaptic 5-HT1A is related to 5-HTT receptor density in the human brain. Neuropsychopharmacology 36, 2258-2265. doi:10.1038/npp.2011.113
26. Bowers, M. B. Jr., Heninger, G. R., and Gerbode, F. (1969). Cerebrospinal fluid 5-hydroxyindoleactiic acid and homovanillic acid in psychiatric patients. Int. J. Neuropharmacol. 8, 255-262. doi:10.1016/0028-3908(69)90046-X
27. Branchi, I. (2011). The double edged sword of neural plasticity: increasing serotonin levels leads to both greater vulnerability to depression and improved capacity to recover. Psychoneuroendocrinology 36, 339-351. doi:10.1016/j.psyneuen.2010. 08.011
28. Brown, R. E., Sergeeva, O. A., Eriksson, K. S., and Haas, H. L. (2002). Conver- gent excitation of dorsal raphe serotonin neurons by multiple arousal systems (orexin/hypocretin, histamine and noradrenaline). J. Neurosci. 22, 8850-8859.
29. Burrows, G. D., Norman, T. R., and Judd, F. K. (1994). Definition and differ- ential diagnosis of treatment-resistant depression. Int. Clin. Psychopharmacol. 9(Suppl. 2), 5-10. doi:10.1097/00004850-199406002-00002
30. Calabrese, J. R., Bowden, C. L., Sachs, G., Yatham, L. N., Behnke, K., Mehtonen, O. P., et al. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psychiatry 64, 1013-1024. doi:10.4088/JCP.v64n0906
31. Calabrese, J. R., Keck, P. E. Jr., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., et al. (2005). A randomized, double-blind, placebo-controlled trial of que- tiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry 162, 1351-1360. doi:10.1176/appi.ajp.162.7.1351
32. Celada, P., Bortolozzi, A., and Artigas, F. (2013). Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs 27, 703-716. doi:10.1007/s40263-013-0071-0
33. Celada, P., Puig, M. V., Casanovas, J. M., Guillazo, G., and Artigas, F. (2001). Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A, GABA(A), and glutamate receptors. J. Neurosci. 21, 9917-9929.
34. Charney, D. S., Menkes, D. B., and Heninger, G. R. (1981). Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. Arch. Gen. Psychiatry 38, 1160-1180. doi:10.1001/archpsyc.1981.01780350094011
35. Chernoloz, O., El Mansari, M., and Blier, P. (2012). Effects of sustained administra- tion of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission. Neuropsychopharmacology 37, 1717-1728. doi:10.1038/npp.2012.18
36. Chun, B. J., and Dunner, D. L. (2004). A review of antidepressant-induced hypo- mania in major depression: suggestions for DSM-V. Bipolar Disord. 6, 32-42. doi:10.1046/j.1399-5618.2003.00084.x
37. Coplan, J., Wolk, S., and Klein, D. (1995). "Anxiety and the serotonin 1A receptor, " in Psychopharmacology: The Fourth Generation of Progress, eds F. E. Bloom and D. J. Kupfer (New York, NY: Raven Press), 1301-1310.
38. Coplan, J. D., Gorman, J. M., and Klein, D. F. (1992). Serotonin related functions in panic-anxiety: a critical overview. Neuropsychopharmacology 6, 189-200.
39. Coplan, J. D., Trost, R. C., Owens, M. J., Cooper, T. B., Gorman, J. M., Nemeroff, C. B., et al. (1998). Cerebrospinal fluid concentrations of somatostatin and biogenic amines in grown primates reared by mothers exposed to manipulated foraging conditions. Arch. Gen. Psychiatry 55, 473-477. doi:10.1001/archpsyc.55.5.473
40. Correa, R., Akiskal, H., Gilmer, W., Nierenberg, A. A., Trivedi, M., and Zisook, S. (2010). Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression? J. Affect. Disord. 127, 10-18. doi:10.1016/j.jad. 2010.06.036
41. Corya, S. A., Williamson, D., Sanger, T. M., Briggs, S. D., Case, M., and Tollefson, G. (2006). A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress. Anxiety 23, 364-372. doi:10.1002/da.20130
42. Cote, T. E., and Yasumura, S. (1975). Effect of ACTH and histamine stress on serum corticosterone and adrenal cyclic AMP levels in immature rats. Endocrinology 96, 1044-1047. doi:10.1210/endo-96-4-1044
43. Cutler, A. J., Montgomery, S. A., Feifel, D., Lazarus, A., Astrom, M., and Brecher, M. (2009). Extended release quetiapine fumarate monotherapy in major depres- sive disorder: a placebo- and duloxetine-controlled study. J. Clin. Psychiatry 70, 526-539. doi:10.4088/JCP.08m04592
44. Daray, F. M., Thommi, S. B., and Ghaemi, S. N. (2010). The pharmacogenetics of antidepressant-induced mania: a systematic review and meta-analysis. Bipolar Disord. 12, 702-706. doi:10.1111/j.1399-5618.2010.00864.x
45. Dell'Osso, B., Palazzo, M. C., Oldani, L., and Altamura, A. C. (2011). The noradren- ergic action in antidepressant treatments: pharmacological and clinical aspects. CNS Neurosci. Ther. 17, 723-732. doi:10.1111/j.1755-5949.2010.00217.x
46. Drevets, W. C., Frank, E., Price, J. C., Kupfer, D. J., Holt, D., Greer, P. J., et al. (1999). PET imaging of serotonin 1A receptor binding in depression. Biol. Psychiatry 46, 1375-1387. doi:10.1016/S0006-3223(99)00189-4
47. Duman, R. S., Heninger, G. R., and Nestler, E. J. (1997). A molecular and cellular theory of depression. Arch. Gen. Psychiatry 54, 597-606. doi:10.1001/archpsyc. 1997.01830190015002
48. Duman, R. S., Malberg, J., Nakagawa, S., and D'Sa, C. (2000). Neuronal plasticity and survival inmood disorders. Biol. Psychiatry 48, 732-739. doi:10.1016/S0006- 3223(00)00935-5
49. Duman, R. S., Malberg, J., and Thome, J. (1999). Neural plasticity to stress and antidepressant treatment. Biol. Psychiatry 46, 1181-1191. doi:10.1016/S0006- 3223(99)00177-8
50. Dwyer, J. M., Lepack, A. E., and Duman, R. S. (2012). mTOR activation is required for the antidepressant effects of mGluR(2)/(3) blockade. Int. J. Neuropsychophar- macol. 15, 429-434. doi:10.1017/S1461145711001702
51. Ferreira Ade, A., Neves, F. S., da Rocha, F. F., Silva, G. S., Romano-Silva, M. A., Miranda, D. M., et al. (2009). The role of 5-HTTLPR polymorphism in antidepressant-associated mania in bipolar disorder. J. Affect. Disord. 112, 267-272. doi:10.1016/j.jad.2008.04.012
52. Fiedorowicz, J. G., Endicott, J., Leon, A. C., Solomon, D. A., Keller, M. B., and Coryell, W. H. (2011). Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am. J. Psychiatry 168, 40-48. doi:10.1176/appi.ajp.2010.10030328
53. Fricker, A. D., Rios, C., Devi, L. A., and Gomes, I. (2005). Serotonin receptor acti- vation leads to neurite outgrowth and neuronal survival. Brain Res. Mol. Brain Res. 138, 228-235. doi:10.1016/j.molbrainres.2005.04.016
54. Frodl, T., Zill, P., Baghai, T., Schule, C., Rupprecht, R., Zetzsche, T., et al. (2008). Reduced hippocampal volumes associated with the long variant of the tri- and diallelic serotonin transporter polymorphism in major depression. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 1003-1007. doi:10.1002/ajmg.b. 30680
55. Frye, M. A., Helleman, G., McElroy, S. L., Altshuler, L. L., Black, D. O., Keck, P. E. Jr., et al. (2009). Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am. J. Psychiatry 166, 164-172. doi:10.1176/appi.ajp.2008.08030322
56. Fulton, S. L. P. V., Reiner, W., Jackowski, A., Perera, T. D., Gorman, J. M., Mathew, S. J., et al. (2014). Cisternal CSF 5-HIAA Inversely Predicts Hippocampal Volume in Nonhuman Primates: Impact of Early Life Stress (ELS) on Serotonin Function. New York, NY: Society of Biological Psychiatry.
57. Gabriel, A. (2006). Lamotrigine adjunctive treatment in resistant unipolar depres- sion: an open, descriptive study. Depress. Anxiety 23, 485-488. doi:10.1002/da. 20211
58. Ghaemi, N., Sachs, G. S., and Goodwin, F. K. (2000). What is to be done? Contro- versies in the diagnosis and treatment of manic-depressive illness. World J. Biol. Psychiatry 1, 65-74. doi:10.3109/15622970009150569
59. Goodwin, G. M., Bowden, C. L., Calabrese, J. R., Grunze, H., Kasper, S., White, R., et al. (2004). A pooled analysis of 2 placebo-controlled 18-month trials of lam- otrigine and lithium maintenance in bipolar I disorder. J. Clin. Psychiatry 65, 432-441. doi:10.4088/JCP.v65n0321
60. Gorman, J. M., Liebowitz, M. R., Fyer, A. J., Goetz, D., Campeas, R. B., Fyer, M. R., et al. (1987). An open trial of fluoxetine in the treatment of panic attacks. J. Clin. Psychopharmacol. 7, 329-332.
61. Gressier, F., Bouaziz, E., Verstuyft, C., Hardy, P., Becquemont, L., and Corruble, E. (2009). 5-HTTLPR modulates antidepressant efficacy in depressed women. Psychiatr. Genet. 19, 195-200. doi:10.1097/YPG.0b013e32832cef0d
62. Gutierrez, R. L., McKercher, R. M., Galea, J., and Jamison, K. L. (2005). Lamotrig- ine augmentation strategy for patients with treatment-resistant depression. CNS Spectr. 10, 800-805.
63. Hammad, T. A., Laughren, T., and Racoosin, J. (2006). Suicidality in pediatric patients treated with antidepressant drugs. Arch. Gen. Psychiatry 63, 332-339. doi:10.1001/archpsyc.63.3.332
64. Healy, D. (2006). The latest mania: selling bipolar disorder. PLoS Med. 3:e185. doi:10.1371/journal.pmed.0030185
65. Himmelhoch, J. M. (1998). Social anxiety, hypomania and the bipolar spectrum: data, theory and clinical issues. J. Affect. Disord. 50, 203-213. doi:10.1016/S0165- 0327(98)00139-6
66. Hirschfeld, R. M., Lewis, L., and Vornik, L. A. (2003). Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depres- sive and manic-depressive association 2000 survey of individuals with bipolar disorder. J. Clin. Psychiatry 64, 161-174. doi:10.4088/JCP.v64n0209
67. Holmes, A., Yang, R. J., Lesch, K. P., Crawley, J. N., and Murphy, D. L. (2003). Mice lacking the serotonin transporter exhibit 5-HT(1A) receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology 28, 2077-2088. doi:10.1038/sj.npp.1300266
68. Huang, G. J., and Herbert, J. (2005). The role of 5-HT1A receptors in the pro- liferation and survival of progenitor cells in the dentate gyrus of the adult hippocampus and their regulation by corticoids. Neuroscience 135, 803-813. doi:10.1016/j.neuroscience.2005.05.056
69. Huang, G. J., and Herbert, J. (2006). Stimulation of neurogenesis in the hippocam- pus of the adult rat by fluoxetine requires rhythmic change in corticosterone. Biol. Psychiatry 59, 619-624. doi:10.1016/j.biopsych.2005.09.016
70. Huezo-Diaz, P., Uher, R., Smith, R., Rietschel, M., Henigsberg, N., Marusic, A., et al. (2009). Moderation of antidepressant response by the serotonin transporter gene. Br. J. Psychiatry 195, 30-38. doi:10.1192/bjp.bp.108.062521
71. Hughes, Z. A., Starr, K. R., Langmead, C. J., Hill, M., Bartoszyk, G. D., Hagan, J. J., et al. (2005). Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur. J. Pharmacol. 510, 49-57. doi:10.1016/j.ejphar.2005.01.018
72. Illi, A., Poutanen, O., Setala-Soikkeli, E., Kampman, O., Viikki, M., Huhtala, H., et al. (2011). Is 5-HTTLPR linked to the response of selective serotonin reup- take inhibitors in MDD? Eur. Arch. Psychiatry Clin. Neurosci. 261, 95-102. doi:10.1007/s00406-010-0126-x
73. Ito, C. (2000). The role of brain histamine in acute and chronic stresses. Biomed. Pharmacother. 54, 263-267. doi:10.1016/S0753-3322(00)80069-4
74. Jordan, S., Koprivica, V., Chen, R., Tottori, K., Kikuchi, T., and Altar, C. A. (2002). The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur. J. Pharmacol. 441, 137-140. doi:10.1016/S0014-2999(02)01532-7
75. Kalen, P., and Wiklund, L. (1989). Projections from the medial septum and diagonal band of Broca to the dorsal and central superior raphe nuclei: a non-cholinergic pathway. Exp. Brain Res. 75, 401-416. doi:10.1007/BF00247947
76. Karg, K., Burmeister, M., Shedden, K., and Sen, S. (2011). The serotonin trans- porter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch. Gen. Psychiatry 68, 444-454. doi:10.1001/archgenpsychiatry.2010.189
77. Katz, G. (2011). Tachyphylaxis/tolerance to antidepressive medications: a review. Isr. J. Psychiatry Relat. Sci. 48, 129-135.
78. Kaufman, J., Yang, B. Z., Douglas-Palumberi, H., Grasso, D., Lipschitz, D., Housh- yar, S., et al. (2006). Brain-derived neurotrophic factor-5-HTTLPR gene inter- actions and environmental modifiers of depression in children. Biol. Psychiatry 59, 673-680. doi:10.1016/j.biopsych.2005.10.026
79. Kaufman, J., Yang, B. Z., Douglas-Palumberi, H., Houshyar, S., Lipschitz, D., Krys- tal, J., et al. (2004). Social supports and serotonin transporter gene moderate depression in maltreated children. Proc. Natl. Acad. Sci. U.S.A. 101, 17316-17321. doi:10.1073/pnas.0404376101
80. Kendler, K. S., Kuhn, J. W., Vittum, J., Prescott, C. A., and Riley, B. (2005). The inter- action of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch. Gen. Psychiatry 62, 529-535. doi:10.1001/archpsyc.62.5.529
81. Kent, J. M., Coplan, J. D., Lombardo, I., Hwang, D. R., Huang, Y., Mawlawi, O., et al. (2002). Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652. Psychopharmacology 164, 341-348. doi:10.1007/s00213- 002-1218-8
82. Khan, A. (2009). Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin. Investig. Drugs 18, 1753-1764. doi:10.1517/13543780903286396
83. Khan, A., Cutler, A. J., Kajdasz, D. K., Gallipoli, S., Athanasiou, M., Robinson, D. S., et al. (2011). A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J. Clin. Psychiatry 72, 441-447. doi:10.4088/JCP.10m06596
84. Klein, D. F. (2008). The loss of serendipity in psychopharmacology. JAMA 299, 1063-1065. doi:10.1001/jama.299.9.1063
85. Lees, G., and Leach, M. J. (1993). Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. Brain Res. 612, 190-199. doi:10.1016/0006-8993(93)91660-K
86. Lejeune, F., Poignant, J. C., and Reure, H. (1988). Electrophysiological study of tianeptine, a new enhancer of serotonin uptake with antidepressant activity. Neurophysiol. Clin. 18, 369-381. doi:10.1016/S0987-7053(88)80093-5
87. Lesch, K. P., Gross, J., Franzek, E., Wolozin, B. L., Riederer, P., and Murphy, D. L. (1995). Primary structure of the serotonin transporter in unipolar depression and bipolar disorder. Biol. Psychiatry 37, 215-223. doi:10.1016/0006-3223(94) 00147-U
88. Lewis, G., Mulligan, J., Wiles, N., Cowen, P., Craddock, N., Ikeda, M., et al. (2011). Polymorphism of the 5-HT transporter and response to antidepressants: ran- domised controlled trial. Br. J. Psychiatry 198, 464-471. doi:10.1192/bjp.bp.110. 082727
89. Li, C. T., Bai, Y. M., Huang, Y. L., Chen, Y. S., Chen, T. J., Cheng, J. Y., et al. (2012). Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br. J. Psychiatry 200, 45-51. doi:10.1192/bjp.bp.110.086983
90. Li, N., Lee, B., Liu, R. J., Banasr, M., Dwyer, J. M., Iwata, M., et al. (2010). mTOR- dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964. doi:10.1126/science.1190287
91. Lira, A., Zhou, M., Castanon, N., Ansorge, M. S., Gordon, J. A., Francis, J. H., et al. (2003). Altered depression-related behaviors and functional changes in the dor- sal raphe nucleus of serotonin transporter-deficient mice. Biol. Psychiatry 54, 960-971. doi:10.1016/S0006-3223(03)00696-6
92. Mann, J. J., Malone, K. M., Diehl, D. J., Perel, J., Cooper, T. B., and Mintun, M. A. (1996). Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. Am. J. Psychiatry 153, 174-182.
93. Masoliver, E., Menoyo, A., Perez, V., Volpini, V., Rio, E. D., Perez, J., et al. (2006). Sero- tonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder. Psychiatr. Genet. 16, 25-29. doi:10.1097/01.ypg.0000180684.26288.d7
94. Mathew, S. J., Coplan, J. D., Smith, E. L., Scharf, B. A., Owens, M. J., Nemeroff, C. B., et al. (2002). Cerebrospinal fluid concentrations of biogenic amines and corticotropin-releasing factor in adolescent non-human primates as a func- tion of the timing of adverse early rearing. Stress 5, 185-193. doi:10.1080/ 1025389021000010521
95. McEwen, B. S., Chattarji, S., Diamond, D. M., Jay, T. M., Reagan, L. P., Svennings- son, P., et al. (2009). The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol. Psychiatry 15, 237-249. doi:10.1038/mp.2009.80
96. McIntyre, R. S., Muzina, D. J., Adams, A., Lourenco, M. T., Law, C. W., Soczynska, J. K., et al. (2009). Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin. Pharmacother. 10, 3061-3075. doi:10.1517/ 14656560903448837
97. McIntyre, R. S., Soczynska, J. K., Woldeyohannes, H. O., Alsuwaidan, M., and Konarski, J. Z. (2007). A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin. Pharmacother. 8, 1211-1219. doi:10.1517/14656566.8. 9.1211
98. Mendels, J., and Frazer, A. (1974). Brain biogenic amine depletion and mood. Arch. Gen. Psychiatry 30, 447-451. doi:10.1001/archpsyc.1974.01760100019004
99. Millan, M. J. (2013). On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal. Int. J. Neuropsychopharmacol. 1-29. doi:10.1017/S1461145712001496
100. Millan, M. J., Lejeune, F., and Gobert, A. (2000). Reciprocal autoreceptor and het- eroreceptor control of serotonergic, dopaminergic and noradrenergic transmis- sion in the frontal cortex: relevance to the actions of antidepressant agents. J. Psychopharmacol. 14, 114-138. doi:10.1177/026988110001400202
101. Min, W., Li, T., Ma, X., Li, Z., Yu, T., Gao, D., et al. (2009). Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepres- sant response. Psychopharmacology (Berl.) 205, 409-417. doi:10.1007/s00213- 009-1550-3
102. Muller, N., and Schwarz, M. J. (2007). The immune-mediated alteration of sero- tonin and glutamate: towards an integrated view of depression. Mol. Psychiatry 12, 988-1000. doi:10.1038/sj.mp.4002006
103. Munafo, M. R., Durrant, C., Lewis, G., and Flint, J. (2009). Gene X environment interactions at the serotonin transporter locus. Biol. Psychiatry 65, 211-219. doi:10.1016/j.biopsych.2008.06.009
104. Mundo, E., Walker, M., Cate, T., Macciardi, F., and Kennedy, J. L. (2001). The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch. Gen. Psychiatry 58, 539-544. doi:10.1001/archpsyc.58.6.539
105. Munger, M. A. (2010). Polypharmacy and combination therapy in the management of hypertension inelderly patients with co-morbid diabetes mellitus. DrugsAging 27, 871-883. doi:10.2165/11538650-000000000-00000
106. Musazzi, L., Milanese, M., Farisello, P., Zappettini, S., Tardito, D., Barbiero, V. S., et al. (2010). Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants. PLoS ONE 5:e8566. doi:10.1371/journal.pone.0008566
107. Nikisch, G., Baumann, P., Wiedemann, G., Kiessling, B., Weisser, H., Hertel, A., et al. (2010). Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J. Clin. Psychopharmacol. 30, 496-503. doi:10.1097/JCP.0b013e3181f2288e
108. Novotny, V., and Faltus, F. (2003). First signs of improvement with tianeptine in the treatment of depression: an analysis of a double-blind study versus fluoxetine. Eur. Neuropsychopharmacol. 13(Suppl. 4), S230. doi:10.1016/S0924-977X(03) 91842-6
109. Papeschi, R., and McClure, D. J. (1971). Homovanillic and 5-hydroxyindoleacetic acid in cerebrospinal fluid of depressed patients. Arch. Gen. Psychiatry 25, 354-358. doi:10.1001/archpsyc.1971.01750160066012
110. Perlis, R. H., Beasley, C. M. Jr., Wines, J. D. Jr., Tamura, R. N., Cusin, C., Shear, D., et al. (2007). Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother. Psychosom. 76, 40-46. doi:10.1159/000096363
111. Perlis, R. H., Mischoulon, D., Smoller, J. W., Wan, Y. J., Lamon-Fava, S., Lin, K. M., et al. (2003). Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol. Psychiatry 54, 879-883. doi:10.1016/S0006-3223(03) 00424-4
112. Perlis, R. H., Uher, R., Ostacher, M., Goldberg, J. F., Trivedi, M. H., Rush, A. J., et al. (2011). Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch. Gen. Psychiatry 68, 351-360. doi:10.1001/archgenpsychiatry.2010.179
113. Perna, G., Favaron, E., Di Bella, D., Bussi, R., and Bellodi, L. (2005). Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology 30, 2230-2235. doi:10.1038/sj.npp. 1300822
114. Popova Nina, K., and Naumenko Vladimir, S. (2013). 5-HT1A receptor as a key player in the brain 5-HT system. Rev. Neurosci. 24, 191-204. doi:10.1515/ revneuro-2012-0082
115. Posternak, M.A., and Zimmerman, M. (2005). Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors:a retrospective study. J. Clin. Psychiatry 66, 705-707. doi:10.4088/JCP.v66n0605
116. Quitkin, F. M., McGrath, P. J., Stewart, J. W., Ocepek-Welikson, K., Taylor, B. P., Nunes, E., et al. (1998). Placebo run-in period in studies of depressive disor- ders. Clinical, heuristic and research implications. Br. J. Psychiatry 173, 242-248. doi:10.1192/bjp.173.3.242
117. Radley, J. J., and Jacobs, B. L. (2002). 5-HT1A receptor antagonist administra- tion decreases cell proliferation in the dentate gyrus. Brain Res. 955, 264-267. doi:10.1016/S0006-8993(02)03477-7
118. Reagan, L. P., Rosell, D. R., Wood, G. E., Spedding, M., Muñoz, C., Rothstein, J., et al. (2004). Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: reversal by tianeptine. Proc. Natl. Acad. Sci. U.S.A. 101, 2179-2184. doi:10.1073/pnas.0307294101
119. Reed, C. R., Kajdasz, D. K., Whalen, H., Athanasiou, M. C., Gallipoli, S., and Thase, M. E. (2012). The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Curr. Med. Res. Opin. 28, 27-39. doi:10.1185/03007995.2011.628303
120. Richardson-Jones, J. W., Craige, C. P., Guiard, B. P., Stephen, A., Metzger, K. L., Kung, H. F., et al. (2010). 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron 65, 40-52. doi:10.1016/j.neuron.2009. 12.003
121. Richardson-Jones, J. W., Craige, C. P., Nguyen, T. H., Kung, H. F., Gardier, A. M., Dranovsky, A., et al. (2011). Serotonin-1A autoreceptors are necessary and suffi- cient for the normal formation of circuits underlying innate anxiety. J. Neurosci. 31, 6008-6018. doi:10.1523/JNEUROSCI.5836-10.2011
122. Risch, N., Herrell, R., Lehner, T., Liang, K. Y., Eaves, L., Hoh, J., et al. (2009). Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 301, 2462-2471. doi:10.1001/jama.2009.878
123. Rocha, F.L., and Hara, C.(2003). Lamotrigine augmentationinunipolar depression. Int. Clin. Psychopharmacol. 18, 97-99. doi:10.1097/00004850-200303000-00006
124. Rousseva, A., Henry, C., van den Bulke, D., Fournier, G., Laplanche, J. L., Leboyer, M., et al. (2003). Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenomics J. 3, 101-104. doi:10.1038/ sj.tpj.6500156
125. Rozeske, R. R., Evans, A. K., Frank, M. G., Watkins, L. R., Lowry, C. A., and Maier, S. F. (2011). Uncontrollable, but not controllable, stress desensitizes 5- HT1A receptors in the dorsal raphe nucleus. J. Neurosci. 31, 14107-14115. doi:10.1523/JNEUROSCI.3095-11.2011
126. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., et al. (2006). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. 354, 1231-1242. doi:10.1056/ NEJMoa052963
127. Rutter, M., Thapar, A., and Pickles, A. (2009). Gene-environment interactions: biologically valid pathway or artifact? Arch. Gen. Psychiatry 66, 1287-1289. doi:10.1001/archgenpsychiatry.2009.167
128. Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., et al. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression.N.Engl. J. Med.356, 1711-1722. doi:10.1056/NEJMoa064135
129. Salvadore, G., Quiroz, J. A., Machado-Vieira, R., Henter, I. D., Manji, H. K., and Zarate, C. A. Jr. (2010). The neurobiology of the switch process in bipolar disor- der: a review. J. Clin. Psychiatry 71, 1488-1501. doi:10.4088/JCP.09r05259gre
130. Sanacora, G., Kendell, S. F., Levin, Y., Simen, A. A., Fenton, L. R., Coric, V., et al. (2007). Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol. Psychiatry 61, 822-825. doi:10.1016/j.biopsych.2006.08.037
131. Sanacora, G., Treccani, G., and Popoli, M. (2012). Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood dis- orders. Neuropharmacology 62, 63-77. doi:10.1016/j.neuropharm.2011.07.036
132. Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., et al. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antide- pressants. Science 301, 805-809. doi:10.1126/science.1083328
133. Santos, M. A., Rocha, F. L., and Hara, C. (2008). Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Prim. Care Companion J. Clin. Psychiatry 10, 187-190. doi:10.4088/PCC.v10n0302
134. Serretti, A., Artioli, P., Zanardi, R., Lorenzi, C., Rossini, D., Cusin, C., et al. (2004). Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder. Psychopharmacology (Berl.) 174, 504-511. doi:10.1007/s00213-004- 1948-x
135. Smits, K. M., Smits, L. J., Peeters, F. P., Schouten, J. S., Janssen, R. G., Smeets, H. J., et al. (2008). The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. Psychiatr. Genet. 18, 184-190. doi:10.1097/YPG. 0b013e3283050aca
136. Souery, D., Amsterdam, J., de Montigny, C., Lecrubier, Y., Montgomery, S., Lipp, O., et al. (1999). Treatment resistant depression: methodological overview and operational criteria. Eur. Neuropsychopharmacol. 9, 83-91. doi:10.1016/S0924-977X(98)00004-2
137. Souery, D., Papakostas, G. I., and Trivedi, M. H. (2006). Treatment-resistant depression. J. Clin. Psychiatry 67(Suppl. 6), 16-22.
138. Stahl, S. M. (2001). Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2. Illustrating their mechanism of action. J. Clin. Psychiatry 62, 923-924. doi:10.4088/JCP.v62n1101
139. Stahl, S.M.(2002). Antipsychoticpolypharmacy:evidence basedoreminence based? Acta Psychiatr. Scand. 106, 321-322. doi:10.1034/j.1600-0447.2002.2e011.x
140. Stein, M. B., Seedat, S., and Gelernter, J. (2006). Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psy- chopharmacology (Berl.) 187, 68-72. doi:10.1007/s00213-006-0349-8
141. Stern, W. C., Johnson, A., Bronzino, J. D., and Morgane, P. J. (1981). Neurophar- macology of the afferent projections from the lateral habenula and substan- tia nigra to the anterior raphe in the rat. Neuropharmacology 20, 979-989. doi:10.1016/0028-3908(81)90029-0
142. Tao, R., Ma, Z., and Auerbach, S. B. (1997). Influence of AMPA/kainate receptors on extracellular 5-hydroxytryptamine in rat midbrain raphe and forebrain. Br. J. Pharmacol. 121, 1707-1715. doi:10.1038/sj.bjp.0701292
143. Thase, M. E., Entsuah, A. R., and Rudolph, R. L. (2001). Remission rates during treat- ment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 178, 234-241. doi:10.1192/bjp.178.3.234
144. Thase, M. E., Macfadden, W., Weisler, R. H., Chang, W., Paulsson, B., Khan, A., et al. (2006). Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J. Clin. Psychopharmacol. 26, 600-609. doi:10.1097/01.jcp.0000248603. 76231.b7
145. Trivedi, M. H., Hollander, E., Nutt, D., and Blier, P. (2008). Clinical evidence and potential neurobiological underpinningsof unresolved symptomsof depression. J. Clin. Psychiatry 69, 246-258. doi:10.4088/JCP.v69n0211
146. Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163, 28-40. doi:10.1176/appi.ajp.163.1.28
147. Uher, R., and McGuffin, P. (2010). The moderation by the serotonin transporter gene of environmental adversity in the etiology of depression: 2009 update. Mol. Psychiatry 15, 18-22. doi:10.1038/mp.2009.123
148. Valentine, G. W., Mason, G. F., Gomez, R., Fasula, M., Watzl, J., Pittman, B., et al. (2011). The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 191, 122-127. doi:10.1016/j.pscychresns.2010.10.009
149. Valentino, R. J., Bey, V., Pernar, L., and Commons, K. G. (2003). Substance P Acts through local circuits within the rat dorsal raphe nucleus to alter serotonergic neuronal activity. J. Neurosci. 23, 7155-7159.
150. Whale, R., Terao, T., Cowen, P., Freemantle, N., and Geddes, J. (2010). Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depres- sive disorder: a systematic review. J. Psychopharmacol. 24, 513-520. doi:10.1177/ 0269881108097714
151. Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., et al. (2013). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CAN- MAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 15, 1-44. doi:10.1111/bdi.12025
152. Zanardi, R., Serretti, A., Rossini, D., Franchini, L., Cusin, C., Lattuada, E., et al. (2001). Factors affecting fluvoxamine antidepressant activity: influence of pin- dolol and 5-HTTLPR in delusional and nondelusional depression. Biol. Psychi- atry 50, 323-330. doi:10.1016/S0006-3223(01)01118-0
153. Zarate, C. A. Jr., Payne, J. L., Quiroz, J., Sporn, J., Denicoff, K. K., Luckenbaugh, D., et al. (2004). An open-label trial of riluzole in patients with treatment- resistant major depression. Am. J. Psychiatry 161, 171-174. doi:10.1176/appi. ajp.161.1.171
154. Zarate, C. A. Jr., Quiroz, J. A., Singh, J. B., Denicoff, K. D., De Jesus, G., Luckenbaugh, D. A., et al. (2005). An open-label trial of the glutamate-modulating agent rilu- zole in combination with lithium for the treatment of bipolar depression. Biol. Psychiatry 57, 430-432. doi:10.1016/j.biopsych.2004.11.023
155. Zarate, C. A. Jr., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., et al. (2006). A randomized trial of an N-methyl-D-aspartate antago- nist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856-864. doi:10.1001/archpsyc.63.8.856
156. Zimmerman, M., Ruggero, C.J., Chelminski, I., and Young, D. (2008). Is bipolar dis- order overdiagnosed? J. Clin. Psychiatry 69, 935-940. doi:10.4088/JCP.v69n0608
157. Zunszain, P. A., Horowitz, M. A., Cattaneo, A., Lupi, M. M., and Pariante, C. M. (2013). Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. Mol. Psychi- atry 18, 1236-1241. doi:10.1038/mp.2013.87